Neos Therapeutics Inc. (NASDAQ:NEOS)’s share price was up 3.5% on Tuesday . The stock traded as high as $6.83 and last traded at $6.83, with a volume of 113,952 shares traded. The stock had previously closed at $6.60.

Several equities analysts have recently weighed in on NEOS shares. Royal Bank Of Canada decreased their price target on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 17th. Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 18th. Wells Fargo & Co. reissued a “buy” rating on shares of Neos Therapeutics in a research note on Wednesday, May 18th. Finally, BMO Capital Markets started coverage on shares of Neos Therapeutics in a research note on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $21.75.

The company has a 50-day moving average price of $8.19 and a 200 day moving average price of $9.40. The stock’s market cap is $107.99 million.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.16) by $0.49. The business had revenue of $1.49 million for the quarter, compared to the consensus estimate of $1.48 million. On average, analysts predict that Neos Therapeutics Inc. will post ($5.38) EPS for the current fiscal year.

In related news, CFO Richard I. Eisenstadt purchased 3,710 shares of the stock in a transaction dated Thursday, August 25th. The shares were acquired at an average cost of $6.82 per share, with a total value of $25,302.20. Following the purchase, the chief financial officer now directly owns 3,710 shares in the company, valued at approximately $25,302.20. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Juergen Martens purchased 10,000 shares of the stock in a transaction dated Monday, June 13th. The shares were bought at an average cost of $9.90 per share, for a total transaction of $99,000.00. Following the completion of the purchase, the insider now owns 10,000 shares in the company, valued at $99,000. The disclosure for this purchase can be found here.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.